CN103539769B - 用作激酶抑制剂和hsp90抑制剂的大环化合物 - Google Patents

用作激酶抑制剂和hsp90抑制剂的大环化合物 Download PDF

Info

Publication number
CN103539769B
CN103539769B CN201310414870.9A CN201310414870A CN103539769B CN 103539769 B CN103539769 B CN 103539769B CN 201310414870 A CN201310414870 A CN 201310414870A CN 103539769 B CN103539769 B CN 103539769B
Authority
CN
China
Prior art keywords
cancer
compound
hydrogen
carcinoma
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310414870.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103539769A (zh
Inventor
N·温辛格尔
S·巴尔吕埃娜
M·卡尔普拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Université de Strasbourg
Original Assignee
NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Université de Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATIONAL CENTER FOR SCIENTIFIC RESEARCH, Université de Strasbourg filed Critical NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Publication of CN103539769A publication Critical patent/CN103539769A/zh
Application granted granted Critical
Publication of CN103539769B publication Critical patent/CN103539769B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
CN201310414870.9A 2006-08-11 2007-08-10 用作激酶抑制剂和hsp90抑制剂的大环化合物 Expired - Fee Related CN103539769B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83715406P 2006-08-11 2006-08-11
US60/837,154 2006-08-11
US85873106P 2006-11-13 2006-11-13
US60/858,731 2006-11-13
CN2007800381410A CN101588799B (zh) 2006-08-11 2007-08-10 用作激酶抑制剂和hsp90抑制剂的大环化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2007800381410A Division CN101588799B (zh) 2006-08-11 2007-08-10 用作激酶抑制剂和hsp90抑制剂的大环化合物

Publications (2)

Publication Number Publication Date
CN103539769A CN103539769A (zh) 2014-01-29
CN103539769B true CN103539769B (zh) 2016-03-16

Family

ID=39082315

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310414870.9A Expired - Fee Related CN103539769B (zh) 2006-08-11 2007-08-10 用作激酶抑制剂和hsp90抑制剂的大环化合物
CN2007800381410A Expired - Fee Related CN101588799B (zh) 2006-08-11 2007-08-10 用作激酶抑制剂和hsp90抑制剂的大环化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2007800381410A Expired - Fee Related CN101588799B (zh) 2006-08-11 2007-08-10 用作激酶抑制剂和hsp90抑制剂的大环化合物

Country Status (7)

Country Link
US (2) US8067412B2 (enExample)
EP (1) EP2136799B1 (enExample)
JP (1) JP5465006B2 (enExample)
CN (2) CN103539769B (enExample)
CA (1) CA2696021C (enExample)
ES (1) ES2651019T3 (enExample)
WO (1) WO2008021213A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212012B2 (en) * 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
JP5465006B2 (ja) 2006-08-11 2014-04-09 ユニベルシテ・ドウ・ストラスブール キナーゼおよびｈｓｐ９０の阻害剤として有用な大環状化合物
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
MX2010005999A (es) 2007-12-07 2010-06-23 Eisai R&D Man Co Ltd Intermediarios en la sintesis de analogos de macrolidos de zearalenona.
US20110190237A1 (en) * 2008-01-15 2011-08-04 Nexgenix Pharmaceuticals Macrocyclic Prodrug Compounds Useful as Therapeutics
JP2011510017A (ja) * 2008-01-15 2011-03-31 ユニベルシテ・ドウ・ストラスブール 治療薬として有用なレゾルシン酸ラクトンの合成
WO2010014617A1 (en) * 2008-07-28 2010-02-04 University Of Kansas Heat shock protein 90 inhibitor dosing methods
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US20110082098A1 (en) * 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
WO2012021974A1 (en) * 2010-08-20 2012-02-23 The Hospital For Sick Children Compositions and methods for treatment of cystic fibrosis and diseases associated with aberrant protein cellular processing
CN107011311A (zh) * 2010-10-22 2017-08-04 斯特拉斯堡大学 用于治疗HSP90相关病状的Pochoxime缀合物
US8987274B2 (en) 2011-10-28 2015-03-24 Merck Sharp & Dohme Corp Macrocycles that increase p53 activity and the uses thereof
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
WO2016196256A2 (en) 2015-06-04 2016-12-08 University Of North Carolina At Greensboro Non-aromatic difluoro analogues of resorcylic acid lactones
WO2022089449A1 (zh) * 2020-10-26 2022-05-05 山东大学 一种特异性热休克蛋白90α亚型抑制剂制备及其应用
WO2025226862A1 (en) * 2024-04-24 2025-10-30 Circle Pharma, Inc. Cyclin inhibitors

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196019A (en) 1964-04-06 1965-07-20 Purdue Research Foundation Anabolic and estrogenic compound and process of making
US3239346A (en) * 1965-02-15 1966-03-08 Commercial Solvents Corp Estrogenic compounds and animal growth promoters
FR96016E (fr) 1966-06-29 1972-05-19 Commercial Solvents Corp Composé utilisable comme supplément alimentaire pour les animaux.
US3453367A (en) 1966-06-29 1969-07-01 Commercial Solvents Corp Methods for treating inflammation with estrogenic compounds
NL131183C (enExample) 1966-12-13
US3758511A (en) 1967-01-18 1973-09-11 Merck & Co Inc Preparation of d,1-zearalenones
US3551454A (en) 1967-07-26 1970-12-29 Merck & Co Inc Preparation of optically active (-)-zearalenone and intermediates therefor
US3586701A (en) 1967-08-24 1971-06-22 Commercial Solvents Corp Norzearalane and its production
US3887583A (en) 1968-05-15 1975-06-03 Commercial Solvents Corp Products and process
US3591608A (en) * 1968-11-15 1971-07-06 Ayerst Mckenna & Harrison Macrocyclic ketolactones
US3621036A (en) 1969-02-27 1971-11-16 Merck & Co Inc Derivatives of zearalane
US3860616A (en) 1969-05-01 1975-01-14 Merck & Co Inc Synthesis of d,1-zearalanol
US3704249A (en) 1969-05-01 1972-11-28 Merck & Co Inc Synthesis of the biologically active diastereoisomer of (-) zearalanol
BE757082A (fr) 1970-02-16 1971-03-16 Commercial Solvents Corp Procede de preparation de nouveaux produits a activite antibacterienne
BE757083A (fr) 1970-02-16 1971-03-16 Commercial Solvents Corp Nouveaux produits a activite antibacterienne
US3687982A (en) 1971-03-09 1972-08-29 Commercial Solvents Corp Separation of mixed diastereoisomers of zearalanol
US3903115A (en) 1972-04-25 1975-09-02 Commercial Solvents Corp Synthesis of zearalanes II and related compounds and intermediates useful in the syntheses thereof
US3957825A (en) 1972-04-25 1976-05-18 Commercial Solvents Corporation Process for synthesizing zearalanone and related compounds
US3901922A (en) 1972-04-25 1975-08-26 Commercial Solvents Corp Synthesis of zearalanone and related compounds and intermediates useful in their synthesis
US3901921A (en) 1972-04-25 1975-08-26 Commercial Solvents Corp Synthesis of zearalanes and related compounds and intermediates useful in the syntheses thereof
US3836544A (en) 1972-04-25 1974-09-17 Commercial Solvents Corp Synthesis of zearalanes ii and related compounds and intermediates useful in the syntheses thereof
US3810918A (en) 1972-04-25 1974-05-14 Commercial Solvent Corp Synthesis of zearalanone
US3852307A (en) 1972-04-25 1974-12-03 Commercial Solvents Corp Synthesis of zearalanone and related compounds
US3925423A (en) 1974-01-22 1975-12-09 Commercial Solvents Corp Resorcyclic acid lactones and their production
US3965275A (en) 1974-02-11 1976-06-22 Commercial Solvents Corporation Composition and method
US3954805A (en) 1974-06-06 1976-05-04 Commercial Solvents Corporation Process for preparing zearalene type compounds
US4035504A (en) 1975-05-12 1977-07-12 Imc Chemical Group, Inc. Method for treating cholesterolemia by administering resorcylic acid lactone derivatives
US4088658A (en) 1976-11-04 1978-05-09 Imc Chemical Group, Inc. Synthesis of dideoxyzearalane and related compounds
US4042602A (en) 1976-11-04 1977-08-16 Imc Chemical Group, Inc. Synthesis of dideoxyzearalane and related compounds
US4228079A (en) 1978-10-30 1980-10-14 W. R. Grace & Co. Dialkoxy monorden derivatives
US4670249A (en) 1985-04-12 1987-06-02 International Minerals & Chemical Corp. Growth-promoting compositions
EP0248916A1 (en) * 1986-06-05 1987-12-16 C.R.C. Compagnia di Ricerca Chimica S.p.A. Method for separation of 3S,7R-3,4,5,6,7,8,9,10,11,12-decahydro-7,14,16-trihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1-one from its 3S,7S-diastereomer
US4751239A (en) 1987-06-29 1988-06-14 International Minerals & Chemical Corp. 6' Carbonate esters of zearalanol and its derivatives
US4778821A (en) 1987-07-15 1988-10-18 International Minerals & Chemical Corp. Method for controlling helmintic parasites
US4849447A (en) 1987-10-13 1989-07-18 Pitman-Moore, Inc. Zearalanol derivatives with anabolic activity
US4902711A (en) 1988-01-19 1990-02-20 Pitman-Moore, Inc. 6' Carbamate esters of zearalanol and its derivatives
KR920000763A (ko) 1990-06-06 1992-01-29 가와무라 요시부미 라디시콜 유도체, 그 제조방법 및 그의 항종양 활성
US5650430A (en) 1990-06-06 1997-07-22 Sankyo Company, Limited Radicicol derivatives, their preparation and their anti-tumor activity
JPH06279279A (ja) 1993-03-26 1994-10-04 Tsumura & Co 血管新生阻害剤
JPH06298764A (ja) 1993-04-15 1994-10-25 Kyowa Hakko Kogyo Co Ltd 免疫抑制剤
US5795910A (en) 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US5731343A (en) 1995-02-24 1998-03-24 The Scripps Research Institute Method of use of radicicol for treatment of immunopathological disorders
ES2149468T3 (es) * 1995-04-26 2000-11-01 Kyowa Hakko Kogyo Kk Derivados de radicicol.
US5710174A (en) 1995-06-07 1998-01-20 Zymo Genetics, Inc. Factor XIIIA inhibitor
JPH09202781A (ja) 1996-01-25 1997-08-05 Sankyo Co Ltd ラディシコール誘導体
NZ331062A (en) 1996-10-25 2000-05-26 Kyowa Hakko Kogyo Company Ltd Radicicol derivatives or pharmacologically acceptable salts which show tyrosine kinase inhibition activity and have antitumor effects
JPH10265381A (ja) 1997-03-24 1998-10-06 Sankyo Co Ltd 血管再狭窄予防剤
WO1999055689A1 (en) 1998-04-24 1999-11-04 Kyowa Hakko Kogyo Co., Ltd. Radicicol derivatives
AU779438B2 (en) 1998-12-24 2005-01-27 Novation Pharmaceuticals Inc. Compounds which affect mRNA stability and uses therefor
JP2000236894A (ja) 1999-02-19 2000-09-05 Kyowa Hakko Kogyo Co Ltd ラディシコールの製造方法
US6887853B2 (en) 2000-06-29 2005-05-03 The Trustees Of Boston University Use of geldanamycin and related compounds for treatment of fibrogenic disorders
US6946456B2 (en) 2000-07-28 2005-09-20 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
JP2004506620A (ja) 2000-08-04 2004-03-04 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 合成サリチリハラミド（ｓａｌｉｃｙｌｉｈａｌａｍｉｄｅ）、アピキュラーレン（ａｐｉｃｕｌａｒｅｎ）およびその誘導体
US6734209B2 (en) 2001-08-03 2004-05-11 Board Of Regents The University Of Texas System Synthetic salicylihalamides, apicularens and derivatives thereof
DE60143204D1 (de) 2000-08-18 2010-11-18 Kyowa Hakko Kirin Co Ltd N-aryl-ä4-Ä7-(alkoxy)Chinazolin-4-ylÜPiperazinylüCarboxamid-Verbindungen als PDGF-Rezeptoren Hemmer
ATE328888T1 (de) * 2000-08-25 2006-06-15 Sloan Kettering Inst Cancer Radicicol und monocillin und ihre analogen und ihre anwendungen
US7439359B2 (en) 2000-11-02 2008-10-21 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
JP2004292315A (ja) 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd Ｔａｋ１阻害剤
US20030211469A1 (en) 2001-07-16 2003-11-13 Lloyd Waxman Inhibiting hepatitis c virus processing and replication
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
JP2003113183A (ja) * 2001-10-05 2003-04-18 Kyowa Hakko Kogyo Co Ltd リウマチ治療剤
WO2003041643A2 (en) * 2001-11-09 2003-05-22 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
EP1519735A4 (en) 2001-12-12 2006-01-11 Conforma Therapeutic Corp ASSAYS AND DEVICES FOR DETERMINING AND MODULATING HSP90 BINDING ACTIVITY
GB0202871D0 (en) 2002-02-07 2002-03-27 Cancer Res Ventures Ltd Assays,methods and means
CA2478065C (en) * 2002-03-08 2013-01-08 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
RU2312863C2 (ru) * 2002-04-17 2007-12-20 Тайсо Фармасьютикал Ко., Лтд. Тоник для роста волос
AU2003264357A1 (en) * 2002-08-29 2004-04-30 Kyowa Hakko Kogyo Co., Ltd. Hsp90 FAMILY PROTEIN INHIBITORS
US20060251574A1 (en) 2002-12-12 2006-11-09 Adeela Kamal Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
JPWO2005018674A1 (ja) 2003-08-22 2006-10-19 協和醗酵工業株式会社 イムノグロブリン遺伝子の転座を伴う疾患の治療薬
US20080108694A1 (en) * 2003-12-19 2008-05-08 Samuel J Danishefsky Novel Macrocycles and Uses Thereof
US20050267087A1 (en) 2004-04-28 2005-12-01 Vassiliki Poulaki Inflammatory eye disease
US20060079494A1 (en) 2004-09-27 2006-04-13 Santi Daniel V Specific kinase inhibitors
US7968096B2 (en) 2005-05-04 2011-06-28 The University Of Vermont And State Agricultural College Methods and compositions for treating toxoplasma
JP5465006B2 (ja) 2006-08-11 2014-04-09 ユニベルシテ・ドウ・ストラスブール キナーゼおよびｈｓｐ９０の阻害剤として有用な大環状化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Search for Hsp90 Inhibitors with Potential Anticancer Activity：Isolation and SAR Studies of Radicicol and Monocillin I from Two Plant-Associated Fungi of the Sonoran Desert;Thomas J. Turbyville et al.;《J. Nat. Prod.》;20060203;第69卷(第2期);178-184 *

Also Published As

Publication number Publication date
US8450305B2 (en) 2013-05-28
US20080146545A1 (en) 2008-06-19
CN101588799B (zh) 2013-09-11
EP2136799A4 (en) 2010-10-27
JP5465006B2 (ja) 2014-04-09
EP2136799A1 (en) 2009-12-30
US20120077775A1 (en) 2012-03-29
US8067412B2 (en) 2011-11-29
ES2651019T3 (es) 2018-01-23
WO2008021213A1 (en) 2008-02-21
CN103539769A (zh) 2014-01-29
CA2696021A1 (en) 2008-02-21
JP2010501478A (ja) 2010-01-21
CN101588799A (zh) 2009-11-25
EP2136799B1 (en) 2017-10-04
CA2696021C (en) 2015-09-29

Similar Documents

Publication Publication Date Title
CN101588799B (zh) 用作激酶抑制剂和hsp90抑制剂的大环化合物
JP6159350B2 (ja) 治療薬として有用なレゾルシン酸ラクトンの合成
AU2014278428A1 (en) Processes of making and crystalline forms of a MDM2 inhibitor
US8329683B2 (en) Treatment of neurofibromatosis with radicicol and its derivatives
CN102015673B (zh) 用作治疗剂的大环前药化合物
EP2173733A2 (en) Compositions and methods comprising analogues of radicicol a
US20140135290A1 (en) Macrocyclic prodrug compounds useful as therapeutics
HK1151522B (en) Macrocyclic prodrug compounds useful as therapeutics
HK1150010B (en) Synthesis of resorcylic acid lactones useful as therapeutic agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160316